Developing a P4 medicine approach to obstructive sleep apnea
Active Project Grant Awarded Last action
- Award ID
- P01HL160471
- Recipient
-
The Trustees Of The University Of Pennsylvania UEI GM1XX56LEP58
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,129,816
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 67% complete
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from USAspending.gov.
Description
- Abstract
- This program is directed at developing a new approach to OSA care based on the principles of precision medicine, with a focus on improving prediction, prevention and personalization. The program has 4 projects and 3 cores to support the work of the investigators. Project 01 (genetics of extreme phenotypes of OSA and associated upper airway anatomy) is focused on identifying both common and rare genetic variants that are associated with risk for OSA. Since OSA has multiple pathways to disease, identifying associated genetic variants is challenging. This project investigates gene variants associated with quantitative intermediate traits for the disorder. The focus is on structural risk factors-both craniofacial dimensions and soft tissues. A focus is on tongue FAT, a specific heritable distribution of FAT that mediates the effect of obesity in causing OSA. Machine learning approaches have been developed to allow quantification of traits of interest from a large number of relevant clinically-obtained CT and MR images in individuals with genetic data. Data from this project will be used in combination with data from ongoing genetic studies to develop a polygenic risk score (PRS) for OSA with wide-applicability. Project 02 (micrornas as biomarkers for obstructive sleep apnea) will study micrornas as a biomarker relevant to OSA using RNA sequencing of all short micrornas. Expression of micrornas is dynamic; they respond to multiple challenges, including hypoxia. Micrornas are being used in development of biomarkers in multiple areas, with supportive data in OSA, albeit in relatively small samples. Thus, we will employ a combination of a hypothesis-driven approach complimented by a broader discovery strategy. Biomarkers will be developed to help identify cases with OSA, as well as to assess effectiveness of therapy and to provide prognostic information about who with OSA will have blood pressure reduction with treatment. Project 03 (mechanisms that account for different symptom subtypes of OSA) will examine the physiological and multi-omics determinants of robustly validated symptom subtypes of OSA. There will be an emphasis on the excessively sleepy subtype, which has been shown to be at elevated cardiovascular risk. We will evaluate whether there are differences in physiological responses during sleep in the different subtypes and/or whether there are genetic, epigenetic, and metabolomic differences. Project 04 (going from genetic associations to identification of causative genes) will focus on identifying causative genes that explain gwas associations. For genes conferring risk for OSA, we will begin with existing gwas data complimented by data from project 01. For sleepiness, this project will start with recently published genetic loci, and include analyses based on genes identified in project 03. We will first use cell-based approaches to identify possible causative genes. The role of these genes will be assessed in high-diversity mouse models (for genes associated with anatomy) and in drosophila and zebrafish (for genes associated with sleepiness).
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $145,979 | |
| Amendment | $0 | |
| Amendment | $2,190,674 | |
| Amendment | $2,292,560 | |
| Original award | $2,500,603 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Geisinger Clinic | $173,243 | |
| Geisinger Clinic | $129,805 | |
| University Of Iceland | $145,979 | |
| University Of Kansas Medical Center Research Institute, Inc. | $50,795 | |
| Texas A & M University | $139,268 | |
| The Ohio State University | $137,920 | |
| The Children's Hospital Of Philadelphia | $124,758 | |
| Geisinger Clinic | $240,798 | |
| Geisinger Clinic | $240,798 | |
| The Governors Of The University Of Calgary | $53,212 | |
| University Of Florida | $26,744 | |
| The Ohio State University | $135,161 | |
| University Of Iceland | $142,522 | |
| The Ohio State University | $19,625 | |
| Cedars-Sinai Medical Center | $18,780 | |
| Texas A & M University | $136,483 | |
| Geisinger Clinic | $169,440 | |
| The Children's Hospital Of Philadelphia | $173,716 | |
| The Ohio State University | $103,440 | |
| The Governors Of The University Of Calgary | $54,298 | |
| University Of Florida | $27,290 | |
| Texas A & M University | $139,268 | |
| University Of Iceland | $145,979 |
Show all 23
Quick answers
Who received award P01HL160471?
P01HL160471 was awarded to The Trustees Of The University Of Pennsylvania by National Heart Lung and Blood Institute (National Institutes of Health) on July 1, 2023.
How much is award P01HL160471 worth?
$7,129,816 has been obligated on P01HL160471.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award